Cargando…

Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine

We summarised four pivotal Randomised Controlled Trials (RCTs) with antirheumatic drugs on the secondary prevention of cardiovascular events. The favourable effects of canakinumab and colchicine confirm (low-grade) inflammation as an independent risk factor for cardiovascular events. While colchicin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lems, Willem, Boers, Maarten, van Vollenhoven, Ronald F, Nurmohamed, Mike
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Treatments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970260/ https://www.ncbi.nlm.nih.gov/pubmed/33727219 http://dx.doi.org/10.1136/rmdopen-2020-001560

Ejemplares similares

Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study
por: Barbulescu, Andrei, et al.
Publicado: (2020)

Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population
por: Hooijberg, Femke, et al.
Publicado: (2020)

Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting
por: Liang, Huifang, et al.
Publicado: (2019)

Are biologics more effective than classical disease-modifying antirheumatic drugs?
por: Nurmohamed, Michael T, et al.
Publicado: (2008)

Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
por: Lo, Chris Wai Hang, et al.
Publicado: (2021)

Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study
por: van Halm, Vokko P, et al.
Publicado: (2006)

(Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis
por: den Uyl, Debby, et al.
Publicado: (2011)

An unfavorable body composition is common in early arthritis patients: A case control study
por: Turk, Samina A., et al.
Publicado: (2018)

Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids
por: van Vollenhoven, Ronald, et al.
Publicado: (2018)

Measurement of stiffness in patients with rheumatoid arthritis in low disease activity or remission: a systematic review
por: van Tuyl, Lilian HD, et al.
Publicado: (2014)

Effectiveness of angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers on total and cardiovascular mortality and morbidity in primary prevention: A nationwide study based on French Health Insurance Data (SNDS)
por: Oger, Emmanuel, et al.
Publicado: (2022)

Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
por: Krieckaert, Charlotte, et al.
Publicado: (2022)

The feasibility of polypill for cardiovascular disease prevention in Asian Population
por: Sukonthasarn, Apichard, et al.
Publicado: (2020)

Outcome measures for adherence data from a medication event monitoring system: A literature review
por: Hartman, Linda, et al.
Publicado: (2018)

Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors
por: Pitt, Bertram, et al.
Publicado: (2015)

Implicit and explicit attitudes towards disease-modifying antirheumatic drugs as possible target for improving medication adherence
por: van Heuckelum, M., et al.
Publicado: (2019)

Non-pharmacological interventions to promote work participation in people with rheumatic and musculoskeletal diseases: a systematic review and meta-analysis from the EULAR taskforce on healthy and sustainable work participation
por: Butink, Maarten H P, et al.
Publicado: (2023)

A non-inferiority trial of an attenuated combination strategy (‘COBRA-light’) compared to the original COBRA strategy: clinical results after 26 weeks
por: den Uyl, Debby, et al.
Publicado: (2014)

Missing data in randomised controlled trials of rheumatoid arthritis drug therapy are substantial and handled inappropriately
por: Khan, Nasim A, et al.
Publicado: (2021)

Confounding by Indication Probably Distorts the Relationship between Steroid Use and Cardiovascular Disease in Rheumatoid Arthritis: Results from a Prospective Cohort Study
por: van Sijl, Alper M., et al.
Publicado: (2014)

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment
por: Schiff, Michael, et al.
Publicado: (2017)

A neutrophil signature is strongly associated with increased cardiovascular risk in gout
por: Vedder, Daisy, et al.
Publicado: (2020)

Associations between antipsychotics and the risk of incident cardiovascular diseases in individuals with schizophrenia: a nested case–control study
por: Peng, Peng, et al.
Publicado: (2023)

Is methotrexate safe for men with an immune-mediated inflammatory disease and an active desire to become a father? Results of a prospective cohort study (iFAME-MTX)
por: Perez-Garcia, Luis Fernando, et al.
Publicado: (2023)

Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study
por: van der Togt, Céleste J T, et al.
Publicado: (2023)

Treating neglected tropical diseases
por: Hopkins, Adrian
Publicado: (2013)

Pneumococcal vaccination in autoimmune rheumatic diseases
por: Rákóczi, Éva, et al.
Publicado: (2017)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF
por: Cachen, Laurie, et al.
Publicado: (2022)

JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications
por: Russell, Mark D, et al.
Publicado: (2023)

Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis
por: Gehin, Johanna Elin, et al.
Publicado: (2021)

Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: an overview of systematic reviews
por: Rodriguez-García, Sebastián Cruz, et al.
Publicado: (2021)

Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease
por: Niitsu, Takayuki, et al.
Publicado: (2023)

When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS)
por: Gvozdenović, Emilia, et al.
Publicado: (2016)

Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial
por: ter Wee, Marieke M, et al.
Publicado: (2017)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
por: Smolen, Josef S, et al.
Publicado: (2014)

Molecular mechanisms of resistance to disease modifying antirheumatic drugs (DMARDs)
por: Jansen, G, et al.
Publicado: (2002)

Nine-year follow-up of local implantation of autologous skeletal myoblasts in a patient with coronary heart disease
por: Zhang, Dingguo, et al.
Publicado: (2013)

Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
por: Gabay, Cem, et al.
Publicado: (2016)

SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period
por: Boekel, Laura, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1e52s0at0q84d5ordk2ordt4f6